Richard S. Levy

CIK: 0001454983

Transaction Breakdown

Open Market Buys (P)1 (1.7%)

High conviction signal

Open Market Sales (S)31 (52.5%)

Position reduction

Option Exercises (M)13 (22.0%)

Derivative conversions

Awards (A)14 (23.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (4)

KNSA

Kiniksa Pharmaceuticals International, plc

Director

KOD

Kodiak Sciences Inc.

Director

MDGL

MADRIGAL PHARMACEUTICALS, INC.

Director

TARA

Protara Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (59 total)

KNSA
Kiniksa Pharmaceuticals International, plc
Aug 1, 2026
Exercise(M)
Direct
403 shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Aug 1, 2026
Award(A)
Restricted Share Units
Direct
403 shares-
KOD
Kodiak Sciences Inc.
Jun 30, 2026
Award(A)
Stock Option (Right to Buy)
Direct
17.7K shares-
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Jun 17, 2026
Award(A)
Direct
454 shares-
TARA
Protara Therapeutics, Inc.
Jun 15, 2026
Award(A)
Stock Option (Right to Buy)
Direct
31K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
May 29, 2026
Award(A)
Share Option
Direct
12.2K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
May 29, 2026
Exercise(M)
Direct
2.8K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
May 29, 2026
Award(A)
Restricted Share Units
Direct
2K shares-
MDGL
MADRIGAL PHARMACEUTICALS, INC.
May 22, 2026
Sale(S)
Direct
40 shares at avg. $506.68$20K
MDGL
MADRIGAL PHARMACEUTICALS, INC.
May 22, 2026
Sale(S)
Direct
343 shares at avg. $514.67$177K
MDGL
MADRIGAL PHARMACEUTICALS, INC.
May 22, 2026
Sale(S)
Direct
40 shares at avg. $512.97$21K
MDGL
MADRIGAL PHARMACEUTICALS, INC.
May 22, 2026
Sale(S)
Direct
439 shares at avg. $512.50$225K
MDGL
MADRIGAL PHARMACEUTICALS, INC.
May 22, 2026
Sale(S)
Direct
657 shares at avg. $515.92$339K
MDGL
MADRIGAL PHARMACEUTICALS, INC.
May 22, 2026
Sale(S)
Direct
723 shares at avg. $516.87$374K
MDGL
MADRIGAL PHARMACEUTICALS, INC.
May 22, 2026
Sale(S)
Direct
610 shares at avg. $511.40$312K
MDGL
MADRIGAL PHARMACEUTICALS, INC.
May 22, 2026
Sale(S)
Direct
80 shares at avg. $519.98$42K
MDGL
MADRIGAL PHARMACEUTICALS, INC.
May 22, 2026
Sale(S)
Direct
151 shares at avg. $510.36$77K
MDGL
MADRIGAL PHARMACEUTICALS, INC.
May 22, 2026
Sale(S)
Direct
782 shares at avg. $518.76$406K
MDGL
MADRIGAL PHARMACEUTICALS, INC.
May 22, 2026
Sale(S)
Direct
1.5K shares at avg. $517.59$775K
MDGL
MADRIGAL PHARMACEUTICALS, INC.
May 22, 2026
Sale(S)
Direct
320 shares at avg. $508.24$163K
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Feb 23, 2026
Exercise(M)
Direct
2.5K shares at avg. $7.36$18K
KNSA
Kiniksa Pharmaceuticals International, plc
Feb 1, 2026
Exercise(M)
Direct
683 shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Feb 1, 2026
Award(A)
Restricted Share Units
Direct
683 shares-
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Jan 26, 2026
Exercise(M)
Direct
4K shares at avg. $16.46$66K
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Nov 13, 2025
Exercise(M)
Direct
2.5K shares at avg. $7.36$18K

		Type	Shares	Price		Ownership
Aug 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	403	-	$0	Direct
Aug 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Award(A) Restricted Share Units	403	-	-	Direct
Jun 30, 2026	KOD Kodiak Sciences Inc.	Award(A) Stock Option (Right to Buy)	17,731	-	-	Direct
Jun 17, 2026	MDGL MADRIGAL PHARMACEUTICALS, INC.	Award(A)	454	-	$0	Direct
Jun 15, 2026	TARA Protara Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	31,000	-	-	Direct
May 29, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Award(A) Share Option	12,158	-	-	Direct
May 29, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	2,799	-	$0	Direct
May 29, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Award(A) Restricted Share Units	2,026	-	-	Direct
May 22, 2026	MDGL MADRIGAL PHARMACEUTICALS, INC.	Sale(S)	40	$506.68	$20,267	Direct
May 22, 2026	MDGL MADRIGAL PHARMACEUTICALS, INC.	Sale(S)	343	$514.67	$176,532	Direct
May 22, 2026	MDGL MADRIGAL PHARMACEUTICALS, INC.	Sale(S)	40	$512.97	$20,519	Direct
May 22, 2026	MDGL MADRIGAL PHARMACEUTICALS, INC.	Sale(S)	439	$512.50	$224,988	Direct
May 22, 2026	MDGL MADRIGAL PHARMACEUTICALS, INC.	Sale(S)	657	$515.92	$338,961	Direct
May 22, 2026	MDGL MADRIGAL PHARMACEUTICALS, INC.	Sale(S)	723	$516.87	$373,694	Direct
May 22, 2026	MDGL MADRIGAL PHARMACEUTICALS, INC.	Sale(S)	610	$511.40	$311,952	Direct
May 22, 2026	MDGL MADRIGAL PHARMACEUTICALS, INC.	Sale(S)	80	$519.98	$41,598	Direct
May 22, 2026	MDGL MADRIGAL PHARMACEUTICALS, INC.	Sale(S)	151	$510.36	$77,064	Direct
May 22, 2026	MDGL MADRIGAL PHARMACEUTICALS, INC.	Sale(S)	782	$518.76	$405,669	Direct
May 22, 2026	MDGL MADRIGAL PHARMACEUTICALS, INC.	Sale(S)	1,497	$517.59	$774,835	Direct
May 22, 2026	MDGL MADRIGAL PHARMACEUTICALS, INC.	Sale(S)	320	$508.24	$162,637	Direct
Feb 23, 2026	MDGL MADRIGAL PHARMACEUTICALS, INC.	Exercise(M)	2,500	$7.36	$18,400	Direct
Feb 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	683	-	$0	Direct
Feb 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Award(A) Restricted Share Units	683	-	-	Direct
Jan 26, 2026	MDGL MADRIGAL PHARMACEUTICALS, INC.	Exercise(M)	4,000	$16.46	$65,840	Direct
Nov 13, 2025	MDGL MADRIGAL PHARMACEUTICALS, INC.	Exercise(M)	2,500	$7.36	$18,400	Direct

1-25 of 59 transactions

About Levy Richard S

Levy Richard S (SEC CIK 0001454983) files insider reports with the SEC as Director of Kiniksa Pharmaceuticals International, plc (KNSA), Director of Kodiak Sciences Inc. (KOD) and Director of MADRIGAL PHARMACEUTICALS, INC. (MDGL). Signal8 also holds filings tied to 1 other company.

Signal8 holds 21 ownership filings by Levy Richard S, all Form 4s, filed between Nov 5, 2024 and Aug 4, 2026. Those filings report 59 transactions, from Nov 1, 2024 to Aug 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Levy Richard S's filings is in LONDON.

Recent filings by Levy Richard S

Aug 1, 2026: Option exercise of KNSA shares (Form 4, code M).
Aug 1, 2026: Grant or award of KNSA derivative securities (Form 4, code A).
Jun 30, 2026: Grant or award of KOD derivative securities (Form 4, code A).
Jun 17, 2026: Grant or award of MDGL shares (Form 4, code A).
Jun 15, 2026: Grant or award of TARA derivative securities (Form 4, code A).

Other insiders filing for Kiniksa Pharmaceuticals International, plc (KNSA)

Ragosa Mark, CHIEF FINANCIAL OFFICER
Patel Sanj K, CHAIRMAN & CEO
Paolini John F., CHIEF MEDICAL OFFICER
Moat Ross, CHIEF OPERATING OFFICER
Megna Michael R, CHIEF ACCOUNTING OFFICER
Quart Barry D, Director

How to read Form 4 transaction codes